Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2017066225) PHARMACOPERONES OF THE V2 RECEPTOR
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2017/066225 International Application No.: PCT/US2016/056502
Publication Date: 20.04.2017 International Filing Date: 12.10.2016
IPC:
A61K 31/428 (2006.01) ,A61K 31/166 (2006.01) ,A61K 31/13 (2006.01) ,G01N 33/53 (2006.01) ,G01N 33/567 (2006.01) ,A61P 43/00 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
41
having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
425
Thiazoles
428
condensed with carbocyclic rings
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
16
Amides, e.g. hydroxamic acids
165
having aromatic rings, e.g. colchicine, atenolol, progabide
166
having the carbon atom of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
13
Amines, e.g. amantadine
G PHYSICS
01
MEASURING; TESTING
N
INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33
Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48
Biological material, e.g. blood, urine; Haemocytometers
50
Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53
Immunoassay; Biospecific binding assay; Materials therefor
G PHYSICS
01
MEASURING; TESTING
N
INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33
Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48
Biological material, e.g. blood, urine; Haemocytometers
50
Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53
Immunoassay; Biospecific binding assay; Materials therefor
566
using specific carrier or receptor proteins as ligand binding reagent
567
utilising isolate of tissue or organ as binding agent
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
43
Drugs for specific purposes, not provided for in groups A61P1/-A61P41/108
Applicants:
TEXAS TECH UNIVERSITY SYSTEM [US/US]; Office of Technology Transfer and Intellectual Property P.O. Box 42007 Lubbock, TX 79409-2007, US
Inventors:
CONN, P., Michael; US
Agent:
CHALKER, Daniel, J.; US
FLORES, Edwin, S.; US
SINGLETTON, Chainey, P.; US
Priority Data:
62/241,44414.10.2015US
Title (EN) PHARMACOPERONES OF THE V2 RECEPTOR
(FR) CHAPERONS PHARMACOLOGIQUES DU RÉCEPTEUR V2
Abstract:
(EN) The present invention includes compositions and methods for treating a subject with a G protein coupled receptors (GPCRs) misfolded, misrouted, or both misfolded and misrouted protein comprising: obtaining a sample from the subject suspected of having a G protein coupled receptor (GPCR) that is misfolded, misrouted, or both misfolded and misrouted; and providing the subject with an effective amount of a pharmacoperone that prevents misfolding, misrouting, or both misfolding and misrouting of the GPCR protein.
(FR) La présente invention concerne des compositions et des procédés pour traiter un sujet présentant un récepteur couplé aux protéines G (GPCR) mal replié, mal acheminé ou à la fois mal replié et mal acheminé, les procédés comprenant les étapes suivantes : obtention d'un échantillon prélevé chez le sujet présentant un récepteur couplé aux protéines G (GPCR) mal replié, mal acheminé ou à la fois mal replié et mal acheminé; et administration au sujet d'une quantité efficace d'un chaperon pharmacologique qui prévient le mauvais repliement, le mauvais acheminement ou à la fois le mauvais repliement et le mauvais acheminement de la protéine GPCR.
front page image
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)